GREY:IMVIF - Post by User
Post by
Hideawayon Apr 16, 2019 10:46am
69 Views
Post# 29632901
ASCO Selection Process and Notification
ASCO Selection Process and Notification
Body
Abstracts of superior quality will be selected by the ASCO Scientific Program Committee for presentation at the 2019 ASCO Annual Meeting and for publication in the 2019 ASCO Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. Each first author will receive a letter of notification via email from the Committee regarding its decision on the abstract by March 29, 2019. It is their responsibility to share this information with all coauthors and study sponsors. If selected for presentation, the presenting author is responsible for registering and securing a hotel for the Annual Meeting.
Regular & Late-Breaking Data Submissions
Body
Abstract submissions are considered for all types of presentation, and as such authors are not permitted to state a preference for presentation type at the time of submission. Abstracts will be judged solely on the data submitted. Statements such as “further data will be presented” are not acceptable and will decrease the likelihood that the abstract will be selected for presentation at the Annual Meeting.
The Biostatistics Core of the Scientific Program Committee will conduct a formal statistical review of all abstracts representing phase III trials and of other abstracts as determined by Program Committee tracks. A member of the Biostatistics Core will be a voting member of each Committee track, and their recommendations regarding the statistical validity of the abstract and its conclusions will influence the selection decisions. Failure to follow the biostatistical guidelines will have a negative impact on the grading of the abstract by the Scientific Program Committee, decreasing the likelihood of presentation at the Annual Meeting.
Trials in Progress
Body
Abstracts will be reviewed by the Scientific Program Committee and evaluated on the following criteria:
- Strength of Science: Does the trial address an important and novel question?
- Trial Design: Are the eligibility criteria, study endpoints, and planned analysis well defined in this abstract?
- Collaboration: Is there potential for investigator collaboration?
- Relevance: Will the results be relevant and of interest to ASCO Annual Meeting community?
- Requirements:
- Trial is registered, open, and enrolling patients
- Abstract does NOT contain preliminary data or results
Abstract Notifications
Body
Each first author (presenting author) will receive an email acknowledging receipt of the abstract after initiating a submission and after completing a submission. The first author (presenting author) will receive a letter of notification from the Program Committee regarding its decision by late March 29, 2019.